Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Clinical
    • Critical Care
    • Procedures
    • COVID-19
  • Practice Management
    • Quality
    • Public Policy
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Learning Portal
    • The Hospital Leader Blog
    • From SHM
    • SIG Spotlight
    • Chapter Spotlight

An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Clinical
    • Critical Care
    • Procedures
    • COVID-19
  • Practice Management
    • Quality
    • Public Policy
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Learning Portal
    • The Hospital Leader Blog
    • From SHM
    • SIG Spotlight
    • Chapter Spotlight

Stroke

  • Article

    A 12-month implantable loop recorder detects more atrial fibrillation than 30-day external monitoring after ischemic stroke

    January 7, 2022

    Dr. Winget Clinical question: In patients with recent ischemic stroke, does monitoring for 12 months with an implantable loop recorder (ILR) detect more atrial fibrillation (AF) than 30 days with...

  • 1
    News

    No serious CV risks for elderly after Pfizer COVID-19 vaccine

    December 2, 2021

    A French study adds to other evidence that the Pfizer mRNA COVID-19 vaccine does not increase the risk for serious cardiovascular adverse events in elderly individuals.

  • 1
    News

    Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT

    November 17, 2021

    The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a phase 3 trial.

  • News

    Is AFib a stroke cause or innocent bystander? The debate continues

    October 5, 2021

    Many believe AFib is a risk marker for stroke, but new evidence suggests it may be a causal risk factor.

  • News

    DOACs best aspirin after ventricular ablation: STROKE-VT

    August 2, 2021

    Cerebrovascular protection was far better on DOACs after catheter ablation for VT or extrasystoles in the trial and may yet be further improved.

  • 1
    News

    Direct oral anticoagulants: Competition brought no cost relief

    July 27, 2021

    Medicare Part D spending since 2011 has far outpaced growth in the use of oral anticoagulants.

  • 1
    News

    Statins again linked to lower COVID-19 mortality

    July 21, 2021

    Patients hospitalized for COVID-19 who had been taking statins had a substantially lower risk of death and severe outcomes than those who weren’t in a large observational study.

  • News

    Reversal agents curb DOAC-related bleeding but deaths still high

    June 17, 2021

    The meta-analysis of more than 4,000 patients also showed thrombotic events were more frequent with andexanet than with 4PCC or idarucizumab.

  • News

    Are left atrial thrombi that defy preprocedure anticoagulation predictable?

    June 11, 2021

    Features that predispose to such persistent LA thrombi, which are not very rare, could potentially guide more targeted TEE screening before rhythm-control procedures.

  • 1
    News

    Single subcutaneous shot offers fast, potent platelet inhibition in STEMI

    June 1, 2021

    The effect was seen within 15 minutes of receiving RUC-4, an investigational glycoprotein IIb/IIIa inhibitor, with no thrombocytopenia, in a phase 2a study.

1 2 3 … 12Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
  • Copyright © 2000-2023 by the Society of Hospital Medicine and related companies. All rights reserved. ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences